



Week 2

ORAL




FIG. 1

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)




FIG. 2

SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS

Cohort I (200 mg/dose)




FIG. 4

Protocol 01-021 (ORAL SAHA)
 ARM A: SOLID TUMOR PATIENTS
 Cohort IIa (400 mg/dose)








FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)



FIG. 6

8-OS-400
(01/18/02)



**10-OS-400
(01/24/02)**

FIG. 7

SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)




Fig. 9A

Oral 200 mg vs. 400 mg (no-fasting)




Fig. 9B

IV 200 mg vs. 400 mg





Fig. 9C


Apparent Half-life of the Oral Dose



Blue=200 mg group (n=3-5); yellow=400 mg group (n=5-10)

Fig. 10

AUC of the Oral Dose



Blue=200 mg group (n=3-5); yellow=400 mg group (n=5-10)

Fig. 11

Bioavailability




Fig. 12




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E

FIG. 14A





FIG. 14B






FIG. 14C




FIG. 14D




FIG. 14E





FIG. 15